{"filings":[{"id":1343120,"accession_number":"0001437749-26-022088","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-06-30T12:30:18+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports Annamycin CR rates 3x control in Phase 2/3 MIRACLE interim","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CR of 43% and 36% for Annamycin arms vs 12% control; CRc 50% and 57% vs 29% control (n=45, ITT).","iDMC unanimously recommended continuing; no statistical significance at interim per O'Brien-Fleming design.","Part A enrollment 67 of 90 (74%); trial remains powered at 80% for final analysis of ~282 subjects.","Results after single cycle; 75.6% of patients over 60, 31.1% pretreated with venetoclax."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1343122,"accession_number":"0001437749-26-022087","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-06-30T12:29:53+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Moleculin Biotech reports warrant exercise for $2.7M; shares outstanding rise to 7.07M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrants to purchase 1,361,500 shares exercised, generating gross proceeds of ~$2.7 million.","As of June 29, 2026, common shares outstanding total 7,065,000.","Corporate presentation posted on company website; no material updates disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":870916,"accession_number":"0001437749-26-019660","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-06-05T12:30:10+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin announces strong physician intent to prescribe Annamycin in R/R AML; likelihood-to-prescribe score 6/7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oncologists reported average likelihood-to-prescribe Annamycin of 6 out of 7, citing deep remissions and reduced cardiotoxicity.","Physicians highlighted Annamycin's biomarker-agnostic applicability and potential to bridge patients to bone marrow transplant.","Payers viewed Annamycin as a potentially valuable addition for R/R AML, driven by efficacy and safety profile.","Key differentiators include MRD-negative responses and reduced cardiotoxicity, especially important for pediatric and repeat dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":733236,"accession_number":"0001437749-26-018819","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-29T13:26:14+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin ASCO data: Annamycin shows no cardiotoxicity at high cumulative doses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pooled analysis of 90 patients: no significant LVEF change (mean diff -0.12%, p=0.84) across doses up to 2,970 mg/m².","Independent Cleveland Clinic review confirms no drug-induced cardiotoxicity across ECGs, biomarkers, and adverse events.","Phase 1b/2 AML study achieved 50% CR, 60% CRc, median overall survival 12.39 months; 50% of responders received transplant.","Pivotal Phase 2b/3 MIRACLE trial unblinding of first 45 patients on track for June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":649804,"accession_number":"0001437749-26-018317","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-26T12:00:24+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin posts corporate presentation on website; no new material details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated May 2026 made available on company website.","No financial results, clinical updates, or guidance provided in the filing.","Presentation content is an image exhibit; no specific data extracted.","This is a routine disclosure; no material changes to company outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609119,"accession_number":"0001437749-26-018242","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-22T20:00:36+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech ASCO abstract on Annamycin cardiac safety shows no cardiotoxicity in 90 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract accepted for poster at 2026 ASCO Annual Meeting (May 29–June 2, Chicago).","Pooled safety analysis of 90 Annamycin patients; median cumulative dose 660 mg/m2.","No significant LVEF change from baseline (mean diff -0.12%, p=0.84); no dose correlation.","CEO highlights potential to provide anthracycline therapy without cardiotoxicity limits.","Company's Phase 1b/2 AML study previously showed 50% CR and median OS of 12.39 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452965,"accession_number":"0001437749-26-017226","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-15T12:30:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moleculin Q1: Cash $10.3M; MIRACLE trial 40% CRc; 45 subjects enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $10.3M as of March 31, 2026; R&D expense $5.4M (up $2.0M YoY) on MIRACLE trial costs.","MIRACLE Phase 2B/3 trial: first 45 subjects enrolled; blinded composite complete remission (CRc) rate of 40%.","First interim unblinding expected June 2026; 90th subject recruitment targeted for Q3 2026.","Completed Q1 2026 financings with ~$8.3M gross proceeds; runway extended into Q3 2026.","Expect to start pancreatic cancer trial in 2H 2026; aiming for rolling NDA submission for R/R AML in 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50402,"accession_number":"0001437749-26-016535","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-13T12:00:58+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports preliminary blinded CR rate ~30% in MIRACLE trial; first unblinding before June 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary blinded CRc >40%, CR ~30% vs. historical ~17-18% for cytarabine alone.","First unblinding of 45-subject data expected before June 30, 2026; ~30 Annamycin + cytarabine vs 15 control.","56 of 90 subjects recruited in Part A as of May 1, 2026; on track for Q3 2026 completion.","Over 30% of subjects are R/R to prior venetoclax regimen, a challenging population.","Annamycin has FDA Fast Track and Orphan Drug Designations for R/R AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":24401,"accession_number":"0001437749-26-016260","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-12T13:30:19+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports Annamycin shows no clinically significant cardiotoxicity in 90-patient pooled analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pooled analysis of 90 R/R AML patients across 5 trials; 78 had source-verified pre/post ejection fraction assessments.","No patients met criteria for clinically significant left ventricular dysfunction; mean ejection fraction stable.","Cardiac safety review conducted by Cleveland Clinic cardio-oncology laboratory.","Data presented at EHA 2026 Congress; Annamycin dosed beyond conventional anthracycline lifetime limits.","Management believes results support broader positioning in AML and other oncology indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94490,"accession_number":"0001437749-26-015762","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech secures Hong Kong patent for liposomal Annamycin through 2040","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hong Kong patent No. 40073244 covers proprietary reconstitution method of liposomal Annamycin, expiring June 25, 2040.","Invention jointly owned with The University of Texas System; extends IP protection across four continents.","Company expects first Phase 3 clinical data release for Annamycin later this quarter.","Existing granted/allowed patents include US, Australia, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, Taiwan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94489,"accession_number":"0001437749-26-013083","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin's Annamycin extends survival >60% in metastatic pancreatic cancer preclinical models at AACR 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median survival 29 days vs 18 days (p=0.0003) in metastatic PDAC models.","Significant tumor volume reduction across multiple PDAC models (p<0.001).","Higher tumor/pancreatic accumulation vs doxorubicin (p<0.0001).","Induced CD8+ and CD4+ T-cell infiltration, suggesting immune activation.","No cardiotoxicity observed; supports Annamycin's differentiated safety profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94488,"accession_number":"0001437749-26-012325","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve issuance of up to 6.4M warrant shares; name change rejected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved issuance of up to 6,367,956 shares upon exercise of warrants issued Feb 20, 2026.","Name change to Moleculin Inc. failed; received 2,015,174 'For' votes but needed majority of 4,933,110 outstanding shares.","Adjournment proposal passed to allow further proxy solicitation if needed.","A total of 2,382,989 shares were present at the Special Meeting, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106915,"accession_number":"0001437749-26-009298","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin enrolls 45th subject in MIRACLE AML trial; interim data unblinding on track for mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["45th subject enrolled in pivotal Phase 2B/3 MIRACLE trial of Annamycin + cytarabine (AnnAraC) for R/R AML.","Interim unblinding of first 45 subjects remains on track for mid-2026; CEO calls it potentially the most important data moment.","Early blinded data among first 30 patients showed 40% composite complete remission rate (30% CR, 10% CR with partial hematologic recovery).","Approximately 35% of subjects had previously failed venetoclax-based therapies; many had adverse genetic markers.","Enrollment progressing toward 90-subject Part A completion expected in Q3 2026; Phase 3 design to follow dose determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106914,"accession_number":"0001437749-26-008951","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech posts investor presentation; no material new information","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished under Item 7.01 on March 19, 2026.","No financial results, operational updates, or guidance provided in the filing.","Presentation is not incorporated by reference into SEC filings.","Exhibit 99.1 is an image exhibit with no extractable text or data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106913,"accession_number":"0001437749-26-008949","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moleculin reports FY2025 results; MIRACLE trial shows 40% blinded CRc rate in first 30 R/R AML patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 R&D expense $15.9M (down from $17.7M), G&A $9.2M; cash $8.9M at year-end; $8.3M raised in Q1 2026; cash runway into Q3 2026.","MIRACLE trial (Phase 2B/3) Annamycin + cytarabine in R/R AML: blinded CRc 40% in first 30 subjects; interim unblinding for 45 patients expected mid-2026.","Pipeline progress: WP1066 Phase 1 pediatric brain tumor trial shows safety and immune response; Annamycin GBM collaboration and pancreatic cancer study initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106912,"accession_number":"0001437749-26-004800","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Moleculin Biotech raises ~$8.3M via warrant exercise inducement; issues new Series H warrants for 6.4M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders exercise 2,122,652 existing warrants at $3.90 per share; gross proceeds ~$8.3M.","Company issues new Series H warrants for up to 6,367,956 shares (300% of exercised) with 5-year term.","New warrant exercise price = lesser of $3.90 or lowest VWAP in 5 trading days post-announcement; floor $0.962.","Shareholder approval required for issuance of new warrant shares; resale registration to be filed by March 31, 2026.","Roth Capital served as financial advisor, receiving 7% of gross proceeds from the warrant exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106911,"accession_number":"0001437749-26-004558","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin posts new investor presentation on website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01 as Regulation FD disclosure with Exhibit 99.1.","Presentation is dated February 2026; actual content is an image exhibit not parsed.","No specific financial, clinical, or operational data disclosed in the 8-K text.","Investors should review the presentation on the company's website for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106910,"accession_number":"0001437749-26-004455","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports 40% blinded CRc in MIRACLE trial; 35 subjects treated, unblinding on track for Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary blinded composite CR rate of 40% (30% CR, 10% CRh) in first 30 subjects; 67% above historical cytarabine CR.","35 subjects treated to date with 11 in screening; targeting first unblinding at 45 subjects, on track for Q1 2026 treatment milestone.","Roughly 35% of treated subjects are venetoclax regimen failures, a challenging population with high unmet need.","Continued absence of cardiotoxicity cited; Annamycin holds FDA Fast Track and Orphan Drug Designation for R/R AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106909,"accession_number":"0001437749-26-004236","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin gets Japanese patent allowance for Annamycin reconstitution methods","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Japan Patent Office issued notice of allowance for Patent App. 2021-577862 covering liposomal Annamycin preparation methods.","Patent expected to issue in coming months; complements existing US and European Annamycin patents.","Annamycin (naxtarubicin) is in Phase 3 for relapsed/refractory AML with FDA Fast Track and Orphan Drug designations.","CEO Klemp states the allowance strengthens international IP for non-cardiotoxic anthracycline therapy.","Additional Annamycin-related patent applications are pending in major jurisdictions worldwide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106908,"accession_number":"0001437749-26-003119","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Moleculin Biotech shareholders approve warrant share issuance, reject name change to Moleculin Inc.","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approved issuance of up to 2,610,823 shares upon exercise of warrants issued Dec 11, 2025; 578,385 For, 68,176 Against.","Name change amendment from Moleculin Biotech, Inc. to Moleculin Inc. failed: 1,124,921 For (needed >1,346,766 majority of outstanding shares).","Adjournment proposal approved (582,534 For, 64,190 Against) to allow further proxy solicitation if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106907,"accession_number":"0001437749-26-001484","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech posts corporate presentation on website; no material new details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished investor presentation dated January 2026 as Exhibit 99.1.","Presentation posted on company website under Item 7.01 Regulation FD disclosure.","No specific financial or clinical updates provided in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106906,"accession_number":"0001437749-26-001140","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports no cardiotoxicity in 90 Annamycin subjects across five trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent expert review of 90 subjects across five clinical trials found no evidence of cardiotoxicity.","65 of 90 subjects received cumulative doses above FDA lifetime max of 550 mg/m2; one exceeded 6,500 mg/m2.","Data reviewed included serial ECGs, echocardiography with global longitudinal strain, and cardiac troponins.","Trials covered acute myeloid leukemia and soft tissue sarcoma, both as monotherapy and with cytarabine.","CEO cites potential for Annamycin to become first non-cardiotoxic anthracycline addressing high unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106905,"accession_number":"0001437749-26-001050","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin: MIRACLE trial unblinding on track for Q1 2026; global expansion to 9 countries","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First unblinding of 45 subjects in pivotal Phase 2B/3 MIRACLE trial for 2L AML expected Q1 2026.","Trial expanded to 9 countries with over 46 sites selected; next unblinding of 90 subjects expected Q3 2026.","Atlantic Health to fund IIT with Annamycin in 3L pancreatic cancer; preclinical data show activity.","WP1066 Phase 2 GBM trial at Northwestern continues; Emory to start pediatric brain tumor trial in 2H 2026.","Non-cardiotoxicity review of Annamycin data to be presented Q1 2026; potential first non-cardiotoxic anthracycline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106904,"accession_number":"0001437749-26-000695","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Moleculin Biotech regains Nasdaq compliance, avoiding delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq staff notified Panel on Jan 6, 2026 that Moleculin regained compliance with Listing Rule 5550(b)(1) (min $2.5M equity).","Company received delist determination on Nov 20, 2025 and had appealed; hearing now cancelled.","Company is in compliance with all applicable Nasdaq continued listing standards as of Jan 6, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123237,"accession_number":"0001437749-25-038478","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Moleculin Biotech Reduces Warrant Exercise Price to $3.90, Boosts Equity Above $10M to Address Nasdaq Delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Entered warrant amendment agreements on Dec 21, 2025 reducing exercise price of Series E, F, G warrants to $3.90 per share.","Amended Series E and F warrants to delete certain anti-dilution provisions and modify Black Scholes Value definition.","Received Nasdaq delisting notice on Nov 20, 2025 for non-compliance with $2.5M equity rule; appealed and hearing set for Jan 20, 2026.","Raised $6.8M from warrant exercise on Dec 9, 2025 and $1.1M from ATM facility; stockholders' equity now exceeds $10.0M.","Panel hearing for Nasdaq appeal scheduled for January 20, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123236,"accession_number":"0001437749-25-038079","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports positive Phase 1 results for WP1066 in pediatric malignant brain tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WP1066 showed no significant toxicity and determined maximum feasible dose in 10 children with high-grade glioma.","Partial tumor response observed in a DIPG patient; anti-tumor immune responses demonstrated via STAT3 suppression.","Results published in Journal of Clinical Investigation Insight; Phase 2 trial warranted based on findings.","Compassionate use in 3 additional children with high-grade glioma also evaluated.","Study funded by Peach Bowl LegACy Fund and CURE Childhood Cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123235,"accession_number":"0001437749-25-038047","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Moleculin Biotech regains Nasdaq bid price compliance after stock closes at $1.00+ for 10 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed compliance with Listing Rule 5550(a)(2) effective Dec 15, 2025.","Cure based on closing bid price at or above $1.00 for 10 consecutive days ending Dec 12.","Previous deficiency notice from June 27, 2025 is now closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123234,"accession_number":"0001437749-25-037414","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Moleculin Biotech raises ~$6.8M via warrant exercise inducement, issues new Series G warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered inducement letters with holders of Series C/D/F warrants to exercise at $6.63 or $6.3219 per share.","Company expects aggregate gross proceeds of up to ~$6.8M from the warrant exercises.","In exchange, issues new Series G warrants to purchase up to 2,610,823 shares (250% of exercised shares) at $6.63, exercisable upon shareholder approval, 5-year term.","New warrants include anti-dilution price reset with a floor of $1.326 per share and cashless exercise feature.","Company to file resale registration statement for Series G warrant shares by Jan 8, 2026, seek SEC effectiveness by Feb 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123233,"accession_number":"0001437749-25-037209","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports MIRACLE AML trial enrollment at 78% of 45-subject interim target","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment increased to 78% of target for first interim unblinding (up from 60% in Nov).","First unblinding will involve 45 subjects; treatment completion expected Q1 2026.","Consented subjects across seven countries; recruitment ongoing beyond the 78% mark.","Part A of trial (90 subjects) expected to complete enrollment in H1 2026.","Blinded response activity tracking within expected range per CEO commentary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123232,"accession_number":"0001437749-25-037084","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin partners with CIC biomaGUNE for preclinical Annamycin glioblastoma study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement supplies Annamycin for investigator-initiated preclinical research at CIC biomaGUNE, Spain.","Studies compare intra-arterial L-Annamycin and Free-Annamycin vs Doxil and free doxorubicin in mouse GBM models.","Principal investigator Jesús Ruiz-Cabello to lead the evaluation of tumor progression.","Annamycin holds FDA Fast Track and Orphan Drug Designation for AML and STS lung metastases.","GBM is the most common malignant brain tumor with median survival of 15 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123231,"accession_number":"0001437749-25-036488","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Moleculin Biotech announces 1-for-25 reverse stock split effective Dec 1, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:25 ratio effective 12:01 a.m. ET on December 1, 2025.","Outstanding shares reduced from ~51.6M to ~2.07M; authorized shares remain at 500M.","Series E and F warrants have potential exercise price adjustments based on VWAP.","No fractional shares issued; cash paid in lieu of fractional interests.","Ticker MBRX unchanged; new CUSIP number 60855D408."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123230,"accession_number":"0001437749-25-036082","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech furnishes November 2025 corporate presentation; content not disclosed in filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing under Item 7.01: corporate presentation posted on company website as Exhibit 99.1.","Presentation date: November 2025. No specific financial or operational data included in the filing.","Company ticker: MBRX (NASDAQ). No changes in guidance, earnings, or leadership disclosed.","Given absence of presentation content, material impact cannot be assessed from this filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123229,"accession_number":"0001437749-25-036006","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Moleculin Biotech receives Nasdaq delisting notice for non-compliance with equity rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received delist determination letter on Nov 20, 2025 for failing to meet $2.5M minimum stockholders' equity requirement.","Nasdaq will delist on Dec 2, 2025 unless Company requests a hearing panel appeal by Nov 28, 2025.","Moleculin intends to appeal the determination to stay suspension and continue trading under symbol MBRX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123228,"accession_number":"0001437749-25-034635","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports 60% enrollment for first interim unblinding of Phase 3 AML trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["60% of target 45 subjects for first interim unblinding of MIRACLE (R/R AML) trial have consented (as of Nov 4, 2025).","Completion of treatment for first 45 subjects expected Q1 2026; unblinding thereafter.","Blinded response activity tracking within expected range based on historical trial arm responses.","CEO notes strong recruitment momentum despite EU bed shortages.","Annamycin has FDA Fast Track and Orphan Drug designations for R/R AML; patent protection through 2040-2045."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123227,"accession_number":"0001437749-25-034263","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech Enters Research Agreement with UNC to Evaluate Annamycin for Pancreatic Cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with University of North Carolina at Chapel Hill for investigator-initiated preclinical research on Annamycin for pancreatic cancer.","Moleculin will supply Annamycin; studies will evaluate liposomal Annamycin vs. Doxil in PDAC GEMM models.","CEO Walter Klemp noted Annamycin's high affinity for pancreas and correlation of topoisomerase II upregulation with poor survival.","Preclinical research is grant-funded and dovetails with recently announced investigator-funded clinical trial in pancreatic cancer patients.","Annamycin has Fast Track Status and Orphan Drug Designations from FDA for AML and STS lung mets, and EMA for relapsed/refractory AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123226,"accession_number":"0001437749-25-032447","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech files 8-K with investor presentation; content not extractable from filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted October 2025 investor presentation on its website.","No specific financial results, clinical milestones, or guidance disclosed in the 8-K text itself.","Exhibit 99.1 is an image; no quantitative data available for analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123225,"accession_number":"0001437749-25-032076","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin granted Australian patent for Annamycin lyophilizate; term until 2040","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Australian Patent No. 2024203598 covers preliposomal Annamycin lyophilizates with improved stability and high purity.","Base patent term extends to June 2040, subject to extension for regulatory approval.","Patent family includes issued U.S., allowed European, and expected Canadian patents.","Annamycin (naxtarubicin) has Fast Track & Orphan Drug designations from FDA for AML and STS lung mets, and EMA Orphan Drug for AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123224,"accession_number":"0001437749-25-031574","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin announces investigator-initiated Phase 1B/2 study of Annamycin for pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1B/2 single-arm study of Annamycin for third-line advanced pancreatic cancer; investigator-initiated by Atlantic Health.","Moleculin supplies Annamycin and maintains IND; Dr. Angela Alistar (Atlantic Health) is principal investigator.","Estimated additional cost to Moleculin ~$1M from 2026 to 2030 for drug supply and testing.","Preclinical data shows Annamycin targets topoisomerase II, correlated with poor survival in pancreatic cancer.","Annamycin (naxtarubicin) has Fast Track and Orphan Drug status for AML; Orphan Drug for STS lung mets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123223,"accession_number":"0001437749-25-031123","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Moleculin Biotech special meeting: name change proposal fails; warrant issuance approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders rejected name change to Moleculin Inc.; needed majority of 36.7M outstanding shares but only 11.3M voted For.","Approved issuance of up to 64.9M shares upon exercise of warrants issued Aug 28, 2025 (4.9M For, 1.5M Against).","Adjournment proposal passed (5.6M For) to allow further proxy solicitation if needed.","Broker non-votes totaled 8.2M for warrants and adjournment proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139915,"accession_number":"0001437749-25-029847","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin gets Canadian patent allowance for Annamycin manufacturing process; term to 2040","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CIPO issued notice of allowance for patent application 3,142,510 covering preliposomal Annamycin lyophilizate preparation.","Patent expected to issue in coming months; base term extends to June 2040, subject to regulatory extension.","Company already holds issued U.S. and allowed European patents for Annamycin; additional applications pending globally.","CEO states this strengthens global IP portfolio for Annamycin as a non-cardiotoxic anthracycline for AML and STS lung mets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139914,"accession_number":"0001437749-25-028604","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech accelerates Phase 3 AML trial recruitment; targets 45 subjects for Q4 2025 unblinding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["13 subjects recruited (10 dosed); target of 20 by end of September 2025.","Expanding to 8 new active sites in September (Spain, Georgia, Poland, Romania, Italy, Lithuania, US) for total 20.","On track to recruit 45th subject in Q4 2025 for first unblinding of efficacy and safety data.","Expects to conclude Part A (75–90 subjects) in first half 2026, then commence Part B (~220 subjects).","CEO cites operational efficiency and investigator enthusiasm; over 30 active sites expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139913,"accession_number":"0001437749-25-028572","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech posts corporate presentation; no material new information extractable from filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation dated September 2025 posted on company website, but exhibit is an image file with no extractable text.","Filing contains no new revenue, clinical trial results, guidance changes, or other material operational updates.","Presentation likely includes overview of pipeline and strategy; specific content cannot be verified from the 8-K filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139912,"accession_number":"0001437749-25-028528","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin enrolls first EU patients in pivotal Phase 3 MIRACLE trial for R/R AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First two subjects enrolled, one treated in Spain; active sites in US, Spain, Ukraine, Georgia, Romania.","Goal to recruit 45 subjects for Part A unblinding by end of 2025; initial data readout in 2H 2025.","Phase 2B/3 adaptive design with Annamycin+cytarabine vs placebo; FDA Fast Track and Orphan Drug designations.","Part A randomizes 1:1:1 to HiDAC+placebo, 190 or 230 mg/m² Annamycin; Part B adds ~220 subjects.","EMA approval conditional on nonclinical GLP results before Part B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139911,"accession_number":"0001437749-25-027975","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Moleculin Biotech raises $6.0M via warrant exercise; issues 64.9M new warrants at $0.55","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $6.0M from immediate cash exercise of 16.2M existing warrants at $0.37/share.","Issues new unregistered Series F warrants to purchase up to 64.9M shares at $0.55, exercisable upon shareholder approval.","New warrants have 5-year term, anti-dilution protection with a floor of $0.11, and a 4.99%/9.99% beneficial ownership cap.","Company to file resale registration statement by Sep 26, 2025; use proceeds for working capital.","Transaction closed Aug 28, 2025; Roth Capital Partners acted as financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139910,"accession_number":"0001437749-25-027798","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Moleculin reports positive Annamycin AML trial: median OS 15 mos for CR, 12 mos for 2L","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b/2 MB-106 trial completed; median OS 15 months for complete remissions (n=8), 12 months for 2L efficacy evaluable (n=9).","Median OS for ITT population (1L-7L) was 9 months, exceeding typical 4-6 months for relapsed AML.","CR rate 36% ITT, 50% in 2L; 50% of CR subjects proceeded to bone marrow transplant; no cardiotoxicity.","Database lock expected Sep 2025; final clinical study report in Q1 2026; Phase 3 MIRACLE trial enrolling first 45 pts.","Authorized common shares increased from 100M to 500M effective Aug 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139909,"accession_number":"0001437749-25-027247","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech posts August 2025 investor presentation; content not disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed 8-K on August 18, 2025, attaching investor presentation as Exhibit 99.1.","Presentation dated August 2025; no specific financial or operational data extracted from the filing.","No changes to previously disclosed guidance or material events evident from the filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139908,"accession_number":"0001437749-25-027241","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Moleculin shareholders approve 5x authorized share increase and reverse split authority","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 100M to 500M (Proposal 8).","Reverse stock split up to 1:20 authorized (Proposal 9); timing not disclosed.","Share issuance for June 23, 2025 warrants (up to 148.7M shares) approved (Proposal 6).","Equity incentive plan shares increased (Proposal 3); say-on-pay approved (Proposal 4).","Supermajority voting amendment failed (Proposal 7); all 6 directors re-elected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139907,"accession_number":"0001437749-25-026357","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moleculin Q2 2025 cash $7.6M; R&D expense down to $3.6M; MIRACLE trial data readout expected by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $7.6M at June 30, 2025, expected to fund operations only into Q4 2025.","R&D expense $3.6M for Q2 2025, down $0.5M from $4.1M in Q2 2024 due to reduced clinical trial activity.","G&A expense flat at $2.1M; no revenue reported for the quarter.","MIRACLE Phase 2B/3 trial expanded to 4 active sites in US, EU, and Georgia; 20+ additional sites expected by end of Q3 2025.","Anticipated unblinded data readout from first 45 subjects in MIRACLE Part A before end of 2025."],"consensus_eps_estimate":-9.2649,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139906,"accession_number":"0001437749-25-024960","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin preclin data: Annamycin shows efficacy in liver cancers; AML readout H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annamycin demonstrated anti-tumor activity in orthotopic HCC models, colorectal liver metastases, and PDAC liver metastases.","Preclinical data show targeted organ accumulation (liver, spleen, lungs, pancreas) vs doxorubicin; no cardiotoxicity seen.","Prior clinical data: 32 of 42 subjects received >FDA lifetime max anthracycline without cardiotoxicity.","Preliminary data readout for Annamycin in AML expected in second half of 2025.","Data presented at Shelby-Lavine Pancreatic Cancer Symposium at MD Anderson Cancer Center."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139905,"accession_number":"0001437749-25-024411","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech furnishes July 2025 corporate presentation; no specific financial data extractable","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted on company website under Item 7.01 FD Disclosure.","Exhibit 99.1 is an image-based presentation; textual content not provided.","No new financial or operational figures available from the filing.","Routine disclosure; no material changes reported in the body of the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-08-01T23:59:59+00:00|139905"}